Iradimed Ownership
| IRMD Stock | USD 54.61 0.53 0.96% |
Shares in Circulation | First Issued 2013-03-31 | Previous Quarter 12.8 M | Current Value 12.8 M | Avarage Shares Outstanding 12 M | Quarterly Volatility 753.7 K |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Iradimed |
Iradimed Stock Ownership Analysis
About 37.0% of the company shares are held by company insiders. The company last dividend was issued on the 24th of February 2025. IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging compatible medical devices, and related accessories and services in the United States and internationally. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida. Iradimed operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 110 people. To learn more about Iradimed Co call Roger Susi at 407 677 8022 or check out https://www.iradimed.com.Besides selling stocks to institutional investors, Iradimed also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Iradimed's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Iradimed's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Iradimed Quarterly Liabilities And Stockholders Equity |
|
Iradimed Insider Trades History
About 37.0% of Iradimed Co are currently held by insiders. Unlike Iradimed's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Iradimed's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Iradimed's insider trades
Iradimed Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Iradimed is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Iradimed Co backward and forwards among themselves. Iradimed's institutional investor refers to the entity that pools money to purchase Iradimed's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2024-12-31 | 143.1 K | Bank Of New York Mellon Corp | 2024-12-31 | 100.1 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 88 K | Rice Hall James & Associates, Llc | 2024-12-31 | 69.9 K | Liontrust Investment Partners Llp | 2024-12-31 | 69.2 K | Charles Schwab Investment Management Inc | 2024-12-31 | 65.8 K | Bridge City Capital, Llc | 2024-12-31 | 61.9 K | Hightower Advisors, Llc | 2024-12-31 | 60 K | Jpmorgan Chase & Co | 2024-09-30 | 58.5 K | Blackrock Inc | 2024-12-31 | 941 K | Nine Ten Capital Management Llc | 2024-12-31 | 905.9 K |
Iradimed Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Iradimed insiders, such as employees or executives, is commonly permitted as long as it does not rely on Iradimed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Iradimed insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Iradimed Outstanding Bonds
Iradimed issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Iradimed uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Iradimed bonds can be classified according to their maturity, which is the date when Iradimed Co has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US462613AP51 Corp BondUS462613AP51 | View | |
| IQVIA Holdings 5 Corp BondUS46266TAA60 | View |
Iradimed Corporate Filings
8K | 13th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 13th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 6th of December 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Iradimed is a strong investment it is important to analyze Iradimed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iradimed's future performance. For an informed investment choice regarding Iradimed Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iradimed. If investors know Iradimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iradimed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.112 | Dividend Share 0.47 | Earnings Share 1.5 | Revenue Per Share | Quarterly Revenue Growth 0.111 |
The market value of Iradimed is measured differently than its book value, which is the value of Iradimed that is recorded on the company's balance sheet. Investors also form their own opinion of Iradimed's value that differs from its market value or its book value, called intrinsic value, which is Iradimed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iradimed's market value can be influenced by many factors that don't directly affect Iradimed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.